Insmed | INSM - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
BioMarin Pharmaceutical USD 193.68M 141K 2026-09
Cytokinetics USD 138.76M 14.33M 2026-06
DBV Technologies USD 235.6M 98.78M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Novartis USD 1.89B 19.47M 2026-09
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09